These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 11915029)

  • 61. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
    Béliveau R; Gingras D; Kruger EA; Lamy S; Sirois P; Simard B; Sirois MG; Tranqui L; Baffert F; Beaulieu E; Dimitriadou V; Pépin MC; Courjal F; Ricard I; Poyet P; Falardeau P; Figg WD; Dupont E
    Clin Cancer Res; 2002 Apr; 8(4):1242-50. PubMed ID: 11948139
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells.
    Nakamura S; Murakami-Mori K; Rao N; Weich HA; Rajeev B
    J Immunol; 1997 May; 158(10):4992-5001. PubMed ID: 9144519
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Basic fibroblast growth factor up-regulates the expression of vascular endothelial growth factor in primary cultured rat astrocytes.
    Liu X; Zheng SX; Zhou LJ; Zhu XZ
    Acta Pharmacol Sin; 2000 Jan; 21(1):19-22. PubMed ID: 11263242
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype.
    Ortéga N; Jonca F; Vincent S; Favard C; Ruchoux MM; Plouët J
    Am J Pathol; 1997 Nov; 151(5):1215-24. PubMed ID: 9358746
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The expression of basic fibroblast growth factor and vascular endothelial growth factor in prostatic adenocarcinoma: correlation with neovascularization.
    Sugamoto T; Tanji N; Sato K; Fujita H; Nishio S; Sakanaka M; Yokoyama M
    Anticancer Res; 2001; 21(1A):77-88. PubMed ID: 11299793
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
    Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
    Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
    Millauer B; Longhi MP; Plate KH; Shawver LK; Risau W; Ullrich A; Strawn LM
    Cancer Res; 1996 Apr; 56(7):1615-20. PubMed ID: 8603410
    [TBL] [Abstract][Full Text] [Related]  

  • 68. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.
    Sgadari C; Barillari G; Toschi E; Carlei D; Bacigalupo I; Baccarini S; Palladino C; Leone P; Bugarini R; Malavasi L; Cafaro A; Falchi M; Valdembri D; Rezza G; Bussolino F; Monini P; Ensoli B
    Nat Med; 2002 Mar; 8(3):225-32. PubMed ID: 11875492
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
    Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
    Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
    Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
    Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells.
    Tran J; Rak J; Sheehan C; Saibil SD; LaCasse E; Korneluk RG; Kerbel RS
    Biochem Biophys Res Commun; 1999 Nov; 264(3):781-8. PubMed ID: 10544009
    [TBL] [Abstract][Full Text] [Related]  

  • 72. VEGF and bFGF are highly expressed in intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia.
    Lappi-Blanco E; Soini Y; Kinnula V; Pääkkö P
    J Pathol; 2002 Feb; 196(2):220-7. PubMed ID: 11793374
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis.
    Jośko J; Gwóźdź B; Jedrzejowska-Szypułka H; Hendryk S
    Med Sci Monit; 2000; 6(5):1047-52. PubMed ID: 11208453
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Neovasculature induced by vascular endothelial growth factor is fenestrated.
    Roberts WG; Palade GE
    Cancer Res; 1997 Feb; 57(4):765-72. PubMed ID: 9044858
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?
    Moon WS; Rhyu KH; Kang MJ; Lee DG; Yu HC; Yeum JH; Koh GY; Tarnawski AS
    Mod Pathol; 2003 Jun; 16(6):552-7. PubMed ID: 12808060
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
    Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
    Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vascular changes in hepatocellular carcinoma.
    Yang ZF; Poon RT
    Anat Rec (Hoboken); 2008 Jun; 291(6):721-34. PubMed ID: 18484619
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Expression of vascular endothelial growth factor correlates with invasion and metastasis of hepatocellular carcinoma].
    Li X; Tang Z; Zhou G
    Zhonghua Zhong Liu Za Zhi; 1998 Jan; 20(1):12-4. PubMed ID: 10921046
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Spatial and temporal expression of angiogenic molecules during tumor growth and progression.
    Kumar R; Kuniyasu H; Bucana CD; Wilson MR; Fidler IJ
    Oncol Res; 1998; 10(6):301-11. PubMed ID: 9848101
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Yanase K; Yoshiji H; Ikenaka Y; Noguchi R; Kitade M; Kaji K; Yoshii J; Namisaki T; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
    Oncol Rep; 2007 Feb; 17(2):441-6. PubMed ID: 17203185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.